

# SECURITIES AND EXCHANGE COMMISSION

## FORM SC 13D/A

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities [amend]

Filing Date: **2021-07-30**  
SEC Accession No. [0001104659-21-097780](#)

([HTML Version](#) on [secdatabase.com](#))

### SUBJECT COMPANY

#### **Liberty Media Corp**

CIK:[1560385](#) | IRS No.: [371699499](#) | State of Incorp.: **DE** | Fiscal Year End: **1231**  
Type: **SC 13D/A** | Act: **34** | File No.: [005-87155](#) | Film No.: [211129366](#)  
SIC: **4833** Television broadcasting stations

Mailing Address	Business Address
<i>12300 LIBERTY BOULEVARD ENGLEWOOD CO 80112</i>	<i>12300 LIBERTY BOULEVARD ENGLEWOOD CO 80112 720-875-5400</i>

### FILED BY

#### **MALONE JOHN C**

CIK:[937797](#) | State of Incorp.: **CO** | Fiscal Year End: **1231**  
Type: **SC 13D/A**

Mailing Address
<i>12300 LIBERTY BLVD ENGLEWOOD CO 80112</i>

---

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

---

SCHEDULE 13D/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 4)\*

---

**LIBERTY MEDIA CORPORATION**

(Name of Issuer)

Series A Liberty SiriusXM Common Stock, par value \$0.01 per share;  
Series B Liberty SiriusXM Common Stock, par value \$0.01 per share;  
Series A Liberty Braves Common Stock, par value \$0.01 per share;  
Series B Liberty Braves Common Stock, par value \$0.01 per share;  
Series A Liberty Formula One Common Stock, par value \$0.01 per share; and  
Series B Liberty Formula One Common Stock, par value \$0.01 per share

---

(Title of Class of Securities)

Series A Liberty SiriusXM Common Stock: 531229409  
Series B Liberty SiriusXM Common Stock: 531229508  
Series A Liberty Braves Common Stock: 531229706  
Series B Liberty Braves Common Stock: 531229805  
Series A Liberty Formula One Common Stock: 531229870  
Series B Liberty Formula One Common Stock: 531229862

---

(CUSIP Numbers)

**John C. Malone**  
c/o Liberty Media Corporation  
12300 Liberty Boulevard  
Englewood, Colorado 80112  
(720) 875-5400

---

(Name, Address and Telephone Number of Person Authorized  
to Receive Notices and Communications)

**July 28, 2021**

---

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

*Note.* Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* § 240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act"), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 531229409 (LSXMA)  
531229508 (LSXMB)  
531229706 (BATRA)  
531229805 (BATRB)  
531229870 (FWONA)  
531229862 (FWONB)

**1** Names of Reporting Persons

John C. Malone

Check the Appropriate Box if a Member of a Group (see instructions)

- 2** (a)   
(b)

**3** SEC Use Only

**4** Source of Funds (see instructions)  
OO

**5** Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

**6** Citizenship or Place of Organization  
U.S.

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person

**7** Sole Voting Power  
Series A Liberty SiriusXM Common Stock: 1,135,428 (1, 2, 3, 4)  
Series B Liberty SiriusXM Common Stock: 9,346,654 (1, 5, 6)  
Series A Liberty Braves Common Stock: 114,271 (1, 2, 3, 4)  
Series B Liberty Braves Common Stock: 934,664 (1, 5, 6)  
Series A Liberty Formula One Common Stock: 285,530 (1, 2, 3, 4)  
Series B Liberty Formula One Common Stock: 2,336,663 (1, 5, 6)

**8** Shared Voting Power  
Series A Liberty SiriusXM Common Stock: 0  
Series B Liberty SiriusXM Common Stock: 108,687 (7)  
Series A Liberty Braves Common Stock: 0  
Series B Liberty Braves Common Stock: 10,868 (7)  
Series A Liberty Formula One Common Stock: 0  
Series B Liberty Formula One Common Stock: 27,171 (7)

**9** Sole Dispositive Power  
Series A Liberty SiriusXM Common Stock: 1,135,428 (1, 2, 3, 4)  
Series B Liberty SiriusXM Common Stock: 9,346,654 (1, 5, 6)  
Series A Liberty Braves Common Stock: 114,271 (1, 2, 3, 4)  
Series B Liberty Braves Common Stock: 934,664 (1, 5, 6)  
Series A Liberty Formula One Common Stock: 285,530 (1, 2, 3, 4)  
Series B Liberty Formula One Common Stock: 2,336,663 (1, 5, 6)

**10** Shared Dispositive Power  
Series A Liberty SiriusXM Common Stock: 0  
Series B Liberty SiriusXM Common Stock: 108,687 (7)  
Series A Liberty Braves Common Stock: 0  
Series B Liberty Braves Common Stock: 10,868 (7)  
Series A Liberty Formula One Common Stock: 0  
Series B Liberty Formula One Common Stock: 27,171 (7)

Aggregate Amount Beneficially Owned by Each Reporting Person	
	Series A Liberty SiriusXM Common Stock: 1,135,428 (1, 2, 3, 4)
	Series B Liberty SiriusXM Common Stock: 9,455,341 (1, 5, 6, 7)
11	Series A Liberty Braves Common Stock: 114,271 (1, 2, 3, 4)
	Series B Liberty Braves Common Stock: 945,532 (1, 5, 6, 7)
	Series A Liberty Formula One Common Stock: 285,530 (1, 2, 3, 4)
	Series B Liberty Formula One Common Stock: 2,363,834 (1, 5, 6, 7)
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) <input type="checkbox"/>
	Percent of Class Represented by Amount in Row (11)
	Series A Liberty SiriusXM Common Stock: 1.2% (8)
	Series B Liberty SiriusXM Common Stock: 96.5% (8)
13	Series A Liberty Braves Common Stock: 1.1% (8)
	Series B Liberty Braves Common Stock: 96.3% (8)
	Series A Liberty Formula One Common Stock: 1.1% (8)
	Series B Liberty Formula One Common Stock: 96.6% (8)
14	Type of Reporting Person (see instructions)
	IN

(1) Includes 101,778 shares of Series A Liberty SiriusXM common stock, par value \$0.01 per share (the "Series A Liberty SiriusXM Common Stock"), 230,564 shares of Series B Liberty SiriusXM common stock, par value \$0.01 per share (the "Series B Liberty SiriusXM Common Stock"), 10,177 shares of Series A Liberty Braves common stock, par value \$0.01 per share (the "Series A Liberty Braves Common Stock"), 23,056 shares of Series B Liberty Braves common stock, par value \$0.01 per share (the "Series B Liberty Braves Common Stock"), 25,444 shares of Series A Liberty Formula One common stock, par value \$0.01 per share (the "Series A Liberty Formula One Common Stock"), and 57,641 shares of Series B Liberty Formula One common stock, par value \$0.01 per share (the "Series B Liberty Formula One Common Stock"), held in a revocable trust (the "LM Revocable Trust") with respect to which John C. Malone ("Mr. Malone") and Mr. Malone's wife, Mrs. Leslie Malone ("Mrs. Malone"), are trustees. Mrs. Malone has the right to revoke such trust at any time. Mr. Malone disclaims beneficial ownership of the shares held by the LM Revocable Trust.

(2) Includes 612,907 shares of Series A Liberty SiriusXM Common Stock, 61,290 shares of Series A Liberty Braves Common Stock and 153,226 shares of Series A Liberty Formula One Common Stock pledged to Fidelity Brokerage Services, LLC in connection with a margin loan facility and 101,778 shares of Series A Liberty SiriusXM Common Stock, 10,177 shares of Series A Liberty Braves Common Stock and 25,444 shares of Series A Liberty Formula One Common Stock pledged to Merrill Lynch, Pierce, Fenner & Smith Incorporated in connection with a margin loan facility.

(3) Does not include shares of Series A Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock or Series A Liberty Formula One Common Stock issuable upon conversion of shares of Series B Liberty SiriusXM Common Stock, Series B Liberty Braves Common Stock and Series B Liberty Formula One Common Stock, respectively, beneficially owned by Mr. Malone; however, if such shares of Series A Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock and Series A Liberty Formula One Common Stock were included, Mr. Malone would have beneficial ownership of (a) 10,590,769 shares of Series A Liberty SiriusXM Common Stock and Mr. Malone's beneficial ownership of Series A Liberty SiriusXM Common Stock would be 9.9% of the total outstanding shares of Series A Liberty SiriusXM Common Stock, subject to the relevant footnotes set forth herein, (b) 1,059,803 shares of Series A Liberty Braves Common Stock and Mr. Malone's beneficial ownership of Series A Liberty Braves Common Stock would be 9.4% of the outstanding shares of Series A Liberty Braves Common Stock, subject to the relevant footnotes set forth herein and (c) 2,649,364 shares of Series A Liberty Formula One Common Stock and Mr. Malone's beneficial ownership of Series A Liberty Formula One Common Stock would be 9.4% of the outstanding shares of Series A Liberty Formula One Common Stock, subject to the relevant footnotes set forth herein.

(4) Includes 250,000 shares of Series A Liberty SiriusXM Common Stock, 25,000 shares of Series A Liberty Braves Common Stock and 62,500 shares of Series A Liberty Formula One Common Stock held by the Malone Family Land Preservation Foundation and 170,743 shares of Series A Liberty SiriusXM Common Stock, 17,804 shares of Series A Liberty Braves Common Stock and 44,360

shares of Series A Liberty Formula One Common Stock held by the Malone Family Foundation, as to which shares Mr. Malone disclaims beneficial ownership.

(5) Includes 490,597 shares of Series B Liberty SiriusXM Common Stock, 49,059 shares of Series B Liberty Braves Common Stock and 122,649 shares of Series B Liberty Formula One Common Stock held by a trust with respect to which Mr. Malone is the sole trustee and, with his wife, retains a unitrust interest in the trust.

(6) The Exchange Agreement (defined and described in Item 6) contains certain provisions relating to the transfer of the Series B Liberty SiriusXM Common Stock, Series B Liberty Braves Common Stock and Series B Liberty Formula One Common Stock beneficially owned by Mr. Malone.

(7) Includes 108,687 shares of Series B Liberty SiriusXM Common Stock, 10,868 shares of Series B Liberty Braves Common Stock and 27,171 shares of Series B Liberty Formula One Common Stock held by two trusts (the "Trusts") which are managed by an independent trustee and of which the beneficiaries are Mr. Malone's adult children. Mr. Malone has no pecuniary interest in the Trusts, but he retains the right to substitute assets held by the Trusts. Mr. Malone disclaims beneficial ownership of the shares held by the Trusts.

(8) Based upon 97,425,637 shares of Series A Liberty SiriusXM Common Stock, 9,802,232 shares of Series B Liberty SiriusXM Common Stock, 10,312,954 shares of Series A Liberty Braves Common Stock, 981,494 shares of Series B Liberty Braves Common Stock, 25,836,549 shares of Series A Liberty Formula One Common Stock and 2,445,895 shares of Series B Liberty Formula One Common Stock, in each case, outstanding as of June 30, 2021, based on information provided by Liberty Media Corporation (the "Issuer"). At the option of the holder, each share of Series B Liberty SiriusXM Common Stock, Series B Liberty Braves Common Stock and Series B Liberty Formula One Common Stock is convertible into one share of Series A Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock and Series A Liberty Formula One Common Stock, respectively. Each share of Series B Liberty SiriusXM Common Stock, Series B Liberty Braves Common Stock and Series B Liberty Formula One Common Stock is entitled to 10 votes, whereas each share of Series A Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock and Series A Liberty Formula One Common Stock is entitled to one vote. Accordingly, Mr. Malone may be deemed to beneficially own voting equity securities of the Issuer representing approximately 48.6% of the voting power with respect to a general election of directors of the Issuer. See Item 5.

---

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**SCHEDULE 13D/A  
(Amendment No. 4)\***

**Statement of**

**JOHN C. MALONE**

**Pursuant to Section 13(d) of the Securities Exchange Act of 1934**

**in respect of**

**LIBERTY MEDIA CORPORATION**

This Amendment No. 4 to Schedule 13D (this "Amendment," and together with the Schedule 13D (as defined below, the "Statement") amends the statement on Schedule 13D originally filed by John C. Malone ("Mr. Malone" or the "Reporting Person") with the Securities and Exchange Commission (the "SEC") on January 22, 2013 (the "Original Statement"), as amended by Amendment No. 1 filed with the SEC by Mr. Malone on December 27, 2013 ("Amendment No. 1"), Amendment No. 2 filed with the SEC by Mr. Malone on April 27, 2016 ("Amendment No. 2") and Amendment No. 3 filed with the SEC by Mr. Malone on September 14, 2016 ("Amendment No. 3" and, together with the Original Statement, Amendment No. 1 and Amendment No. 2, the "Schedule 13D"), and

relates to (i) the Series A Liberty SiriusXM common stock, par value \$0.01 per share (the “Series A Liberty SiriusXM Common Stock”), (ii) the Series B Liberty SiriusXM common stock, par value \$0.01 per share (the “Series B Liberty SiriusXM Common Stock”), (iii) the Series A Liberty Braves common stock, par value \$0.01 per share (the “Series A Liberty Braves Common Stock”), (iv) the Series B Liberty Braves common stock, par value \$0.01 per share (the “Series B Liberty Braves Common Stock”), (v) the Series A Liberty Formula One common stock, par value \$0.01 per share (the “Series A Liberty Formula One Common Stock”), and (vi) the Series B Liberty Formula One common stock, par value \$0.01 per share (the “Series B Liberty Formula One Common Stock”) and together with the Series A Liberty SiriusXM Common Stock, Series B Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock, the Series B Liberty Braves Common Stock and the Series A Liberty Formula One Common Stock, the “Common Stock”). Capitalized terms used but not defined in this Amendment have the meanings given to such terms in the Schedule 13D. Except as set forth herein, the Schedule 13D is unmodified.

#### **Item 1. Security And Issuer**

Item 1 of the Schedule 13D is hereby amended and restated to read as follows:

On January 24, 2017, Liberty Media Corporation (the “Issuer”) filed a Restated Certificate of Incorporation with the Delaware Secretary of State to, among other things, (i) change the name of the “Liberty Media Common Stock” to the “Liberty Formula One Common Stock” and (ii) reclassify each share of each series of the Issuer’s then-existing Liberty Media Common Stock into one share of the corresponding series of Liberty Formula One Common Stock solely to effect the name change.

Mr. Malone is filing this Schedule 13D with respect to the following series of common stock of the Issuer, beneficially owned by Mr. Malone:

- (a) Series A Liberty SiriusXM Common Stock, par value \$0.01 per share;
- (b) Series B Liberty SiriusXM Common Stock, par value \$0.01 per share;
- (c) Series A Liberty Braves Common Stock, par value \$0.01 per share;

4

---

- (d) Series B Liberty Braves Common Stock, par value \$0.01 per share;
- (e) Series A Liberty Formula One Common Stock, par value \$0.01 per share; and
- (f) Series B Liberty Formula One Common Stock, par value \$0.01 per share.

The Issuer’s executive offices are located at 12300 Liberty Boulevard, Englewood, Colorado 80112.

Pursuant to Rule 13d-3 under the Exchange Act, this Statement also relates to the shares of Series A Liberty SiriusXM Common Stock issuable upon the conversion of shares of Series B Liberty SiriusXM Common Stock, the shares of Series A Liberty Braves Common Stock issuable upon the conversion of shares of Series B Liberty Braves Common Stock and the shares of Series A Liberty Formula One Common Stock issuable upon the conversion of shares of Series B Liberty Formula One Common Stock. At the option of the holder, each share of Series B Liberty SiriusXM Common Stock is convertible into one share of Series A Liberty SiriusXM Common Stock, each share of Series B Liberty Braves Common Stock is convertible into one share of Series A Liberty Braves Common Stock and each share of Series B Liberty Formula One Common Stock is convertible into one share of Series A Liberty Formula One Common Stock. Shares of Series A Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock and Series A Liberty Formula One Common Stock are not convertible. The holders of Series A Liberty SiriusXM Common Stock, Series B Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock, Series B Liberty Braves Common Stock, Series A Liberty Formula One Common Stock and Series B Liberty Formula One Common Stock generally vote together as a single class with respect to all matters voted on by the stockholders of the Issuer. The holders of Series B Liberty SiriusXM Common Stock, Series B Liberty Braves Common Stock and Series B Liberty Formula One Common Stock are entitled to 10 votes per share and the holders of Series A Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock and Series A Liberty Formula One Common Stock are entitled to one vote per share.

#### **Item 4. Purpose of the Transaction**

Item 4 of the Schedule 13D is hereby amended and supplemented to include the following information:

The information set forth in Item 6 of this Amendment and the exhibit listed in Item 7 of this Amendment are incorporated into this Item 4 by reference.

Mr. Malone holds and has acquired the shares of Common Stock described herein for investment purposes.

Other than as set forth in this Statement, Mr. Malone does not have any present plans or proposals which relate to or would result in: (i) any acquisition by any person of additional securities of the Issuer, or any disposition of securities of the Issuer; (ii) any extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (iii) any sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (iv) any change in the board or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any vacancies on the board; (v) any material change in the present capitalization or dividend policy of the Issuer; (vi) any other material change in the Issuer's business or corporate structure; (vii) any change in the Issuer's charter or bylaws or other actions which may impede the acquisition of control of the Issuer by any person; (viii) any delisting from a national securities exchange or any loss of authorization for quotation in an inter-dealer quotation system of a registered national securities association of a class of securities of the Issuer; (ix) any termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended, of a class of equity securities of the Issuer; or (x) any action similar to any of those enumerated above.

Mr. Malone is Chairman of the Board of Directors of the Issuer. As a result, Mr. Malone regularly has discussions with members of Issuer management, board members of the Issuer, and stockholders of the Issuer, which discussions from time to time relate to management, governance and board composition, the Issuer's operations and financial condition or strategic transactions.

Notwithstanding the foregoing, Mr. Malone may determine to change his intentions with respect to the Issuer at any time in the future and may, for example, elect (i) to acquire additional shares of Common Stock or (ii) to dispose of all or a portion of his holdings of shares of Common Stock, as the case may be, in each subject to the terms of the Exchange Agreement. In reaching any determination as to his future course of action, Mr. Malone will take into consideration various factors, such as the Issuer's business and prospects, other developments concerning the Issuer, other business opportunities available to Mr. Malone, tax and estate planning considerations, liquidity needs and general economic and stock market conditions, including, but not limited to, the market price of the Common Stock.

#### **Item 5. Interest in Securities of the Issuer.**

Item 5 of the Schedule 13D is hereby amended and restated to read as follows:

(a) - (b) Mr. Malone beneficially owns (without giving effect to the conversion of shares of Series B Liberty SiriusXM Common Stock, Series B Liberty Braves Common Stock or Series B Liberty Formula One Common Stock into shares of Series A Liberty SiriusXM Common Stock, Series A Liberty Braves Common Stock and Series A Liberty Formula One Common Stock, respectively) (i) 1,135,428 shares of Series A Liberty SiriusXM Common Stock (including (A) 101,778 shares held by a revocable trust (the "LM Revocable Trust") with respect to which Mr. Malone and his wife are trustees and as to which shares Mr. Malone disclaims beneficial ownership and (B) 250,000 shares held by the Malone Family Land Preservation Foundation and 170,743 shares held by the Malone Family Foundation, as to which shares Mr. Malone disclaims beneficial ownership), which represent approximately 1.2% of the outstanding shares of Series A Liberty SiriusXM Common Stock, (ii) 9,455,341 shares of Series B Liberty SiriusXM Common Stock (including (A) 230,564 shares held by the LM Revocable Trust, as to which shares Mr. Malone disclaims beneficial ownership, (B) 490,597 shares held by a trust with respect to which Mr. Malone is the sole trustee and, with his wife, retains a unitrust interest in the trust (the "CRT") and (C) 108,687 shares held by two trusts (the "Trusts") over which Mr. Malone has a right of substitution which are managed by an independent trustee and the beneficiaries of which are Mr. Malone's adult children and as to which shares Mr. Malone disclaims beneficial ownership), which represent approximately 96.5% of the outstanding shares of Series B Liberty SiriusXM Common Stock, (iii) 114,271 shares of Series A Liberty Braves Common Stock (including (A) 10,177 shares held by the LM Revocable Trust as to which shares Mr. Malone disclaims beneficial ownership and (B) 25,000 shares held by the Malone Family Land Preservation Foundation and 17,804 shares held by the Malone Family Foundation, as to which shares Mr. Malone disclaims beneficial ownership), which represent approximately 1.1% of the outstanding shares of Series A Liberty Braves Common Stock, (iv) 945,532

shares of Series B Liberty Braves Common Stock (including (A) 23,056 shares held by the LM Revocable Trust, as to which shares Mr. Malone disclaims beneficial ownership, (B) 49,059 shares held by the CRT and (C) 10,868 shares held by the Trusts, as to which shares Mr. Malone disclaims beneficial ownership), which represent approximately 96.3% of the outstanding shares of Series B Liberty Braves Common Stock, (v) 285,530 shares of Series A Liberty Formula One Common Stock (including (A) 25,444 shares held by the LM Revocable Trust, as to which shares Mr. Malone disclaims beneficial ownership and (B) 62,500 shares held by the Malone Family Land Preservation Foundation and 44,360 shares held by the Malone Family Foundation, as to which shares Mr. Malone disclaims beneficial ownership), which represent approximately 1.1% of the outstanding shares of Series A Liberty Formula One Common Stock, and (vi) 2,363,834 shares of Series B Liberty Formula One Common Stock (including (A) 57,641 shares held by the LM Revocable Trust, as to which shares Mr. Malone disclaims beneficial ownership, (B) 122,649 shares held by the CRT and (C) 27,171 shares held by the Trusts, as to which shares Mr. Malone disclaims beneficial ownership), which represent approximately 96.6% of the outstanding shares of Series B Liberty Formula One Common Stock.

The foregoing percentage interests are based on 97,425,637 shares of Series A Liberty SiriusXM Common Stock, 9,802,232 shares of Series B Liberty SiriusXM Common Stock, 10,312,954 shares of Series A Liberty Braves Common Stock, 981,494 shares of Series B Liberty Braves Common Stock, 25,836,549 shares of Series A Liberty Formula One Common Stock and 2,445,895 shares of Series B Liberty Formula One Common Stock, in each case, outstanding as of June 30, 2021, based on information provided by the Issuer. Accordingly, Mr. Malone may be deemed to beneficially own voting equity securities of the Issuer representing approximately 48.6% of the voting power with respect to a general election of directors of the Issuer.

Mr. Malone and, to his knowledge, the LM Revocable Trust, the CRT, the Malone Family Land Preservation Foundation and the Malone Family Foundation each have the sole power to vote and to dispose of, or to direct the voting or disposition of, their respective shares of Common Stock, subject to the terms of the Exchange Agreement (defined and described in Item 6). The Trusts hold 108,687 shares of Series B Liberty SiriusXM Common Stock, 10,868 shares of Series B Liberty Braves Common Stock and 27,171 shares of Series B Liberty Formula One Common Stock, as to which shares Mr. Malone has no pecuniary interest and disclaims beneficial ownership. To Mr. Malone's knowledge, the Trusts have the sole power to vote and to dispose of, or to direct the voting or disposition of, the shares of Common Stock held by the Trusts, except that Mr. Malone is permitted under the terms of the Trusts to substitute assets in the Trusts and thereby may acquire any shares held in the Trusts at any time.

(c) Except as disclosed in this Amendment, neither Mr. Malone nor, to his knowledge, the LM Revocable Trust, the CRT, the Malone Family Land Preservation Foundation, the Malone Family Foundation or the Trusts, has executed any transactions in respect of the Common Stock within the last sixty days.

(d) Not Applicable.

(e) Not Applicable.

**Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is hereby amended and supplemented to read as follows:

Exchange Agreement

On July 28, 2021, the Issuer entered into an Exchange Agreement (as defined below) with Mr. Malone, whereby, among other things, Mr. Malone agreed to an arrangement under which his aggregate voting power in the Issuer would not exceed 49% (the "Target Voting Power") plus 0.5% (under certain circumstances). As of June 30, 2021, Mr. Malone beneficially owned shares of Common Stock constituting approximately 48.6% of the aggregate outstanding voting power of the Issuer, including approximately 47.5%, 47.6% and 49.0% of the outstanding voting power of the Issuer's Braves Group tracking stock, Formula One Group tracking stock and Liberty Sirius XM Group tracking stock, respectively. The Issuer has an ongoing stock repurchase program which permits the Issuer to purchase shares of Series A or Series C of any of the Issuer's Liberty SiriusXM Group common stock, Braves Group common stock and Formula One Group common stock. In light of Mr. Malone's current ownership interests in the Issuer, absent the Exchange Agreement, continued repurchases of the Issuer's Series A shares pursuant to this program would be expected to have the effect of increasing Mr. Malone's aggregate voting power in the Issuer to greater than 50%. The Issuer and its board of directors (the "Board") believe it is in the best interests of the Issuer and its stockholders to not have a single stockholder control greater than 50% of its aggregate voting



power and to maintain flexibility with respect to future share repurchases and other transactions that may have an accretive voting power effect.

A special committee of independent and disinterested directors was formed by the Board to consider a potential exchange arrangement between the Issuer and Mr. Malone and engaged independent legal counsel and financial advisors to assist it. The special committee recommended to the Board the approval of an exchange agreement, among the Issuer, Mr. Malone and a revocable trust of which Mr. Malone is the sole trustee and beneficiary (the “JM Trust”) (the “Exchange Agreement”). The Board, upon the unanimous recommendation of the members of the special committee, approved the Exchange Agreement.

The Exchange Agreement provides for exchanges by the Issuer and Mr. Malone or the JM Trust of shares of Series B Liberty SiriusXM Common Stock, Series B Liberty Braves Common Stock, Series B Liberty Formula One Common Stock for shares of Series C Liberty SiriusXM common stock, par value \$0.01 per share (“Series C Liberty SiriusXM Common Stock”), Series C Liberty Braves common stock, par value \$0.01 per share (“Series C Liberty Braves Common Stock”), and Series C Liberty Formula One common stock, par value \$0.01 per share (“Series C Liberty Formula One Common Stock”), respectively, in connection with certain events, as described below.

*Accretive Event Exchange.* In connection with any event that would result in a reduction in the outstanding votes of any of the Issuer’s tracking stock groups (each, a “Group”) or an increase of Mr. Malone’s beneficially-owned voting power in any Group (other than a Voting Power Exchange (as defined below)) (an “Accretive Event”), in each case, such that Mr. Malone’s voting power with respect to such Group would exceed the Target Voting Power plus 0.5%, Mr. Malone or the JM Trust will be required to exchange with the Issuer shares of Series B common stock of such Group (“Exchanged Group Series B Shares”) for an equal number of shares of Series C common stock of the same Group so as to maintain Mr. Malone’s voting power with respect to such Group as close as possible to, without exceeding, the Target Voting Power, on the terms and subject to the conditions of the Exchange Agreement. For example, repurchases by the Issuer of shares of its capital stock, conversions of Series B shares of a Group into Series A shares of such Group, as well as purchases by Mr. Malone of the Issuer’s capital stock, in each case, having the effect on Mr. Malone’s voting power described above would be Accretive Events.

*Dilutive Event Exchange.* From and after the occurrence of any Accretive Event, in connection with any event that would result in an increase in the outstanding votes of any Group or a decrease of Mr. Malone’s beneficially-owned voting power in any Group (a “Dilutive Event”), in each case, such that Mr. Malone’s voting power with respect to such Group falls below the Target Voting Power less 0.5%, Mr. Malone and the JM Trust may exchange with the Issuer shares of Series C common stock of a Group for an equal number of shares of Series B common stock of the same Group equal to the lesser of (i) the number of shares of Series B common stock of the same Group which would maintain Mr. Malone’s voting power with respect to such Group as close as possible to, without exceeding, the Target Voting Power and (ii) the number of Exchanged Group Series B Shares at such time, on the terms and subject to the conditions of the Exchange Agreement. For example, exercises of stock options for, conversions of convertible securities into or issuances of new shares of the Issuer’s voting stock having the effect on Mr. Malone’s voting power described above would be Dilutive Events.

*Voting Power Exchange.* On a quarterly basis or in connection with any annual or special meeting of stockholders, if Mr. Malone’s aggregate voting power in the Issuer is less than the Target Voting Power and would continue to be less than the Target Voting Power upon completion of a Voting Power Exchange, upon request by Mr. Malone or the JM Trust, the Issuer will be required to exchange with Mr. Malone and the JM Trust shares of Series B common stock of any Group on a one-for-one basis for shares of Series C common stock of the same Group (each such exchange, a “Voting Power Exchange”). The maximum number of shares that may be delivered to Mr. Malone or the JM Trust in any Voting Power Exchange is equal to the number of Exchanged Group Series B Shares at such time that may be delivered without resulting in Mr. Malone’s aggregate voting power in the Issuer exceeding the Target Voting Power. If any Voting Power Exchange would result in Mr. Malone’s voting power with respect to any Group exceeding the Target Voting Power, on any matter submitted by the Issuer to the stockholders of that Group, voting together as a separate class, for approval, Mr. Malone and the JM Trust will vote, or cause to be voted, the portion of their voting power of such Group that exceeds the Target Voting Power in the same manner and in the same proportion as voted by the holders of voting securities of that Group other than Mr. Malone and his controlled affiliates.

*Fundamental Event Exchange.* If the Issuer proposes to consummate any combination, consolidation, merger, exchange offer, split-off, spin-off, rights offering or dividend, in each case, as a result of which holders of Series B common stock of one or more

Groups are entitled to receive securities of the Issuer, securities of another person, property or cash, or a combination thereof (a “Fundamental Event”) then, unless the consideration to be received by holders of Series B common stock and Series C common stock of such Group is identical, either (x) the Issuer will provide for Mr. Malone or the JM Trust to receive, in respect of each Group, as applicable, the same per share amount and form of consideration to be received by holders of Series B common stock of such Group in connection with such event for each Exchanged Group Series C Share (defined below) of the same Group or (y) immediately prior to the consummation of the Fundamental Event, the Issuer will deliver to Mr. Malone and the JM Trust all Exchanged Group Series B Shares in exchange for all Exchanged Group Series C Shares. “Exchanged Group Series C Shares” means the number of shares of Series C common stock of any Group then beneficially owned by Mr. Malone equal to the number of Exchanged Group Series B Shares of the same Group. In connection with certain Fundamental Events where Mr. Malone would beneficially own 40% or more of the aggregate voting power of the surviving or resulting company and serve as an officer or director, such company and Mr. Malone will negotiate an agreement to replicate the benefits and obligations of the Exchange Agreement.

*Restriction on Transfer.* Mr. Malone may transfer his rights to the Exchanged Group Series B Shares only in limited circumstances and only to certain related permitted transferees who sign an agreement replicating the benefits and obligations of the Exchange Agreement.

*Termination.* The Exchange Agreement will terminate with respect to any particular Group upon (i) the parties’ mutual consent, (ii) the execution of a successor exchange agreement between the Issuer and one or more proposed permitted transferees covering all shares of Series B common stock of such Group then beneficially owned by Mr. Malone and all Exchanged Group Series B Shares of such Group or (iii) Mr. Malone’s voting power in such Group falling below 20%. In addition, the Exchange Agreement will terminate in its entirety, upon (i) the parties’ mutual consent, (ii) the execution of a successor exchange agreement between the Issuer and one or more proposed permitted transferees covering all shares of the Issuer’s Series B common stock then beneficially owned by Mr. Malone and all Exchanged Group Series B Shares or (iii) Mr. Malone’s aggregate voting power in the Issuer falling below 20%.

*Expenses.* Under the Exchange Agreement, the Issuer has agreed to pay (or reimburse) Mr. Malone for all reasonable out-of-pocket costs and expenses incurred by Mr. Malone in connection with the preparation, negotiation, execution and consummation of the transactions contemplated by the Exchange Agreement.

The Exchange Agreement is included as Exhibit 7(a) to this Amendment. The foregoing description of the Exchange Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, the Exchange Agreement which is incorporated herein by reference.

#### Pledging Arrangements

Of the shares of Common Stock beneficially owned by Mr. Malone, 612,907 shares of Series A Liberty SiriusXM Common Stock, 61,290 shares of Series A Liberty Braves Common Stock and 153,226 shares of Series A Liberty Formula One Common Stock are pledged to Fidelity Brokerage Services, LLC (“Fidelity”) in connection with a margin loan facility and 101,778 shares of Series A Liberty SiriusXM Common Stock, 10,177 shares of Series A Liberty Braves Common Stock and 25,444 shares of Series A Liberty Formula One Common Stock are pledged to Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) in connection with a margin loan facility.

Additionally, (i) 4,426,016 shares of Series C Liberty SiriusXM Common Stock, 1,095,806 shares of Series C Liberty Braves Common Stock and 1,125,226 shares of Series C Liberty Formula One Common Stock are pledged to Fidelity in connection with a margin loan facility; (ii) 2,734,766 shares of Series C Liberty SiriusXM Common Stock, 623,550 shares of Series C Liberty Braves Common Stock, and 1,157,226 shares of Series C Liberty Formula One Common Stock, in the aggregate, are pledged to Merrill Lynch in connection with margin loan facilities; and (iii) 7,264,000 shares of Series C Liberty SiriusXM Common Stock, 977,500 shares of Series C Liberty Braves Common Stock and 1,875,000 shares of Series C Liberty Formula One Common Stock are pledged to Bank of America in connection with a margin loan facility.

#### **Item 7. Material to be Filed as Exhibits.**

Item 7 of the Schedule 13D is hereby amended and restated to read as follows:

<b>Exhibit No.</b>	<b>Description</b>
7(a)	Exchange Agreement, dated as of July 28, 2021, by and among John C. Malone, the John C. Malone 1995 Revocable Trust U/A DTD 3/6/1995 and Liberty Media Corporation.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

July 29, 2021

/s/ John C. Malone

John C. Malone

[Signature Page to JCM SC 13D/A]

---

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
<u>7(a)</u>	<u><a href="#">Exchange Agreement, dated as of July 28, 2021, by and among John C. Malone, the John C. Malone 1995 Revocable Trust U/A DTD 3/6/1995 and Liberty Media Corporation.</a></u>

---

## EXCHANGE AGREEMENT

This Exchange Agreement (this “Agreement”) is made and entered into as of July 28, 2021, by and among John C. Malone (“Dr. Malone”), the John C. Malone 1995 Revocable Trust U/A DTD 3/6/1995 (the “Trust”) and Liberty Media Corporation, a Delaware corporation (the “Company”).

## RECITALS

WHEREAS, as of June 30, 2021, Dr. Malone beneficially owns shares of Common Stock constituting approximately 48.6% of the outstanding voting power of the Company and approximately 47.5%, 47.6% and 49.0% of the outstanding voting power of the Braves Group, the Formula One Group and the Sirius XM Group, respectively; and

WHEREAS, the Company and Dr. Malone have agreed to enter into the arrangements contemplated by this Agreement in light of, among other things, the fact that the Malone Voting Power in reference to each Group and the Company could become a majority.

NOW, THEREFORE, in consideration of the covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1. Definitions.

“Accretive Event Notice” has the meaning set forth in Section 3(a).

“Accretive Event” means, with respect to the Voting Securities of a Group, any event resulting in (i) the decrease of the Outstanding Votes of such Group, whether by repurchase, redemption, conversion of the Voting Securities of such Group (including any conversion of shares of Series B Common Stock of such Group into shares of Series A Common Stock of such Group) or otherwise or (ii) Dr. Malone’s beneficial ownership of Voting Securities of such Group increasing (excluding through a Voting Power Exchange), in either case, without duplication and immediately following which, and after taking into account any concurrent or substantially concurrent other event resulting in (a) the effects described in clauses (i) or (ii) above, (b) the effects described in clause (i) or (ii) of the definition of Dilutive Event or (c) a Fundamental Event, the Malone Voting Power with respect to such Group would be greater than 0.5% plus the Target Voting Power.

“Action” means any claim, audit, action, suit, proceeding, arbitration, mediation or investigation by or before any Governmental Authority.

“Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such specified Person, for so long as such Person remains so affiliated to the specified Person. For purposes of this definition, and for the avoidance of doubt, natural persons shall not be deemed to be Affiliates of each other.

---

“Agreement” has the meaning set forth in the preamble.

“Available Series B Shares” means, with respect to a Group, at the time of any determination thereof, a number of shares of Series B Common Stock of such Group equal to (x) the aggregate number of Reverse Exchange Shares of such Group delivered to the Company at any one or more Reverse Exchange Closings occurring prior to such time of determination, minus (y) the aggregate number of shares of Series B Common Stock of such Group delivered to Dr. Malone or the Trust at any one or more prior Dilutive Event Exchange Closings, Fundamental Event Exchange Closings, or Voting Power Exchange Closings occurring prior to such time of determination. For the avoidance of doubt, there are no Available Series B Shares of any Group as of the date of this Agreement.

“beneficial owner”, “beneficial ownership” and “beneficially owns” have the meanings given to such terms in Rule 13d-3 under the Exchange Act, and beneficial ownership of capital stock or any other equity security which is then entitled to vote generally in the election of directors shall be calculated in accordance with the provisions of such Rule; provided, however, that, for purposes of determining beneficial ownership, (a) in respect of Dr. Malone or any Proposed Transferee, such Person shall be deemed to be the beneficial owner of any Equity which may be acquired by such Person (disregarding any conditions or legal impediments to such beneficial ownership), whether within sixty (60) days or thereafter, upon the conversion, exchange or exercise of any warrants, options, rights or other securities, (b) notwithstanding clause (a), none of Dr. Malone or any Proposed Transferee shall be deemed to beneficially own any Available Series B Shares unless and until Dr. Malone or such Proposed Transferee, as applicable, acquires such shares at an Exchange Closing pursuant to the terms of this Agreement, and Dr. Malone will cease to beneficially own any shares of Series B Common Stock upon delivery of such shares to the Company at any Reverse Exchange Closing, (c) notwithstanding clause (a), Dr. Malone shall not be deemed to beneficially own any shares of Series A Common Stock into which any shares of Series B Common Stock beneficially owned by Dr. Malone may be converted pursuant to the Company Charter, (d) Dr. Malone shall not be deemed to beneficially own any Equity solely as a result of Dr. Malone’s execution of this Agreement or Dr. Malone’s filing of any reports, forms or schedules with the SEC or other Governmental Authority in connection with any of the matters contemplated hereby, (e) Dr. Malone and any Proposed Transferee shall be deemed, respectively, to beneficially own any Voting Securities beneficially owned by any respective Controlled Affiliate of such Person, and (f) notwithstanding clause (b) above, a Proposed Transferee shall be deemed to beneficially own, any Available Series B Shares that would be the subject of any Successor Exchange Agreement.

“Board” means the board of directors of the Company.

“Braves Group” shall have the meaning ascribed thereto in the Company Charter as of the date of determination.

“Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law to be closed in the City of New York.

“Code” means the Internal Revenue Code of 1986, as amended.

“Common Stock” means any or all Common Stock of the Company designated as such in the Company Charter.

“Company” has the meaning set forth in the preamble.

“Company Bylaws” means the Bylaws of the Company, as amended from time to time.

“Company Charter” means the Restated Certificate of Incorporation of the Company, as amended from time to time.

“Company Exchange Shares” means (i) any shares of Series C Common Stock issued and/or delivered in a Reverse Exchange and (ii) any Available Series B Shares issued and/or delivered in a Dilutive Event Exchange, Fundamental Event Exchange or Voting Power Exchange.

“Company Rescission Shares” shall have the meaning set forth in Section 6(b).

“Competition Law” means any Law that is designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or lessening of competition through merger or acquisition or restraint of trade.

“Controlled Affiliate” means with respect to any Person, any other Person (other than an individual) controlled by such Person. For the purpose of this definition, the term “control” (including, with a correlative meaning, the term “controlled by”), as used with respect to any Person, means (i) beneficial ownership, directly or indirectly, of securities of any Person that represent more than 50% of the vote in the election of directors (or equivalent), (ii) otherwise being entitled to nominate or designate, directly or indirectly, a majority of the directors (or equivalent) or (iii) in the case of a limited partnership or limited liability company, being a general partner or managing member and having the power to direct the policies, management and affairs of such entity.

“Delaware Courts” has the meaning set forth in Section 15.

“Dilutive Event” means, with respect to the Voting Securities of a Group, any event resulting in (i) the increase of the Outstanding Votes of such Group, whether upon the exercise of stock options, conversion of any convertible security, issuance of capital stock or otherwise, or (ii) Dr. Malone’s beneficial ownership of Voting Securities of such Group decreasing, immediately following which, and after taking into account any concurrent or substantially concurrent other event resulting in (a) the effects described in clauses (i) or (ii) above, (b) the effects described in clauses (i) or (ii) of the definition of Accretive Event, or (c) a Fundamental Event, the Malone Voting Power in respect of such Group would be less than the Target Voting Power minus 0.5%.

“Dilutive Event Exchange” has the meaning set forth in Section 2(d)(iii).

“Dilutive Event Exchange Closing” has the meaning set forth in Section 2(b).

“Dilutive Event Notice” has the meaning set forth in Section 2(a).

“Dr. Malone” has the meaning set forth in the preamble.

“Encumbrance” means any mortgage, deed of trust, lien (statutory or otherwise), pledge, hypothecation, charge, title retention device, restriction, covenant, title defect, assignment, adverse claim, encumbrance, option, right of first refusal or first offer, preemptive right or security interest of any kind or nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).

“Equity” means any and all shares of capital stock and securities issuable upon the conversion, exercise or exchange of securities.

“Exchange” means a Dilutive Event Exchange, a Reverse Exchange, a Voting Power Exchange, or a Fundamental Event Exchange.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“Exchange Closing” means a Dilutive Event Exchange Closing, a Reverse Exchange Closing, a Fundamental Event Exchange Closing or a Voting Power Exchange Closing.

“Exchange Event” means a Dilutive Event, an Accretive Event or a Fundamental Event.

“Family Member” means a descendant of a parent of either John C. Malone or Leslie A. Malone, or any trust whose sole beneficiaries are one or more descendants of a parent of either John C. Malone or Leslie A. Malone and, in the case of a charitable remainder trust, a charitable beneficiary.

“Formula One Group” shall have the meaning ascribed thereto in the Company Charter as of the date of determination.

“Fundamental Event” means any combination, consolidation, merger, exchange offer, split-off, spin-off, rights offering or dividend, in each case, as a result of which holders of Series B Common Stock of one or more Groups are entitled to receive securities of the Company, securities of another Person, property or cash, or a combination thereof.

“Fundamental Event Exchange” has the meaning set forth in Section 4(a)(ii).

“Fundamental Event Exchange Closing” has the meaning set forth in Section 4(a)(ii).

“Governmental Authority” means any supranational, national, federal, state, county, local or municipal government, or other political subdivision thereof, or any court, tribunal or arbitral body and any entity exercising executive, legislative, judicial, regulatory, taxing, administrative, prosecutorial or arbitral functions of or pertaining to government, domestic or foreign; *provided*, that such term shall not include any stock exchange or listing company.

“Group” means, as applicable, the Sirius XM Group, the Braves Group or the Formula One Group, or any other tracking stock group that may be created from time to time after the date hereof which is intended to track the performance of a specified group of assets and businesses of the Company. For the avoidance of doubt, in the event the Company Charter is amended to eliminate the tracking stock capitalization structure of the Company, the term “Group” shall refer to the Company.

“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder.

“Independent Director” means a member of the Board who (i) qualifies as an “Independent Director” as defined in the NASDAQ Marketplace Rules or who qualifies as “independent” under the applicable rules and regulations of any other national securities exchange on which the Common Stock is publicly traded on or after the date hereof and (ii) is independent for purposes of Delaware law (as determined in good faith by the Board) from Dr. Malone and, in connection with approval of a Successor Exchange Agreement, from any counterparties thereto.

“Law” means all foreign, federal, state, provincial, local or municipal laws (including common law), statutes, ordinances, regulations and rules of any Governmental Authority, and all Orders.

“Malone Rescission Shares” shall have the meaning set forth in Section 6(b).

“Malone Series C Exchangeable Shares” means, with respect to any Group, and at the time of any determination thereof, a number of shares of Series C Common Stock of such Group equal to the number of Available Series B Shares of such Group at such time.

“Malone Voting Power” means, at the time of any determination thereof, (i) when used in reference to a particular Group, the aggregate voting power of the Voting Securities of such Group with respect to which Dr. Malone has beneficial ownership as a percentage of the voting power of all outstanding Voting Securities of such Group and (ii) when used in reference to the Company, the aggregate voting power of the Voting Securities of the Company with respect to which Dr. Malone has beneficial ownership as a percentage of the voting power of all outstanding Voting Securities of the Company.

“Maximum Amount” has the meaning set forth in Section 5(a).

“Order” means any judgment, order, writ, award, preliminary or permanent injunction or decree of any Governmental Authority.

“Other Voting Securities” has the meaning set forth in Section 5(a).

“Outstanding Votes” means, at the time of any determination thereof, and in respect of any Group, the total number of votes that may be cast by the holders of the outstanding Voting Securities of such Group in their capacity as such at any meeting of stockholders of the Company at which matters generally voted on by the holders of Voting Securities are to be considered.

“Permitted Encumbrance” means (i) any Encumbrance under this Agreement (including, without limitation, pursuant to Section 6 hereof), and (ii) any restrictions on Transfer arising under securities Laws of general applicability.

“Person” means any individual, corporation, limited liability company, limited or general partnership, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Authority or any group comprised of two (2) or more of the foregoing.

“Proposed Transferee” means any Family Member or group of Family Members (as group is used in Section 13(d) under the Exchange Act) to whom Dr. Malone (or his executors, administrators or testamentary trustees) or the Trust proposes to Transfer (or does Transfer) Voting Securities.

“Rescission” has the meaning set forth in Section 6(a).

“Rescission Exchange” has the meaning set forth in Section 9.

“Reverse Exchange” has the meaning set forth in Section 3(c)(iii).

“Reverse Exchange Closing” has the meaning set forth in Section 3(b).

“Reverse Exchange Shares” has the meaning set forth in Section 3(c)(i).

“SEC” means the United States Securities and Exchange Commission.

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Series A Common Stock” means (i) the series of Common Stock designated as “Series A Liberty Sirius XM Common Stock” in the Company Charter, (ii) the series of Common Stock designated as “Series A Liberty Braves Common Stock” in the Company Charter, (iii) the series of Common Stock designated as “Series A Liberty Formula One Common Stock” in the Company Charter and (iv) any other series of voting Common Stock created after the date hereof in respect of a newly created Group the holders of which are generally entitled to the lowest positive number of votes per share for series of Common Stock with respect to such Group in matters submitted to the stockholders of the Company for a vote.

“Series B Common Stock” means (i) the series of Common Stock designated as “Series B Liberty Sirius XM Common Stock” in the Company Charter, (ii) the series of Common Stock designated as “Series B Liberty Braves Common Stock” in the Company Charter, (iii) the series of Common Stock designated as “Series B Liberty Formula One Common Stock” in the Company Charter and (iv) any other series of voting Common Stock created after the date hereof in respect of a newly created Group the holders of which are generally entitled to the highest number of votes per share for series of Common Stock with respect to such Group in matters submitted to the stockholders of the Company for a vote.

“Series C Common Stock” means (i) the series of Common Stock designated as “Series C Liberty Sirius XM Common Stock” in the Company Charter, (ii) the series of Common Stock designated as “Series C Liberty Braves Common Stock” in the Company Charter, (iii) the series of Common Stock designated as “Series C Liberty Formula One Common Stock” in the Company Charter and (iv) any other series of nonvoting Common Stock created after the date hereof in respect of a newly created Group.

“Sirius XM Group” shall have the meaning ascribed thereto in the Company Charter as of the date of determination.

“Special Committee” means any committee of the Board consisting solely of Independent Directors.

“Successor Exchange Agreement” means an exchange agreement between the Company and one or more Proposed Transferees, in substantially the form of this Agreement (as determined in good faith by a Special Committee or a majority of the Independent Directors) with such modifications as are reasonably necessary such that if, as of the time of execution of such exchange agreement, such Proposed Transferee’s beneficial ownership of any Group as a percentage of the voting power of all outstanding Voting Securities of such Group is (or would be, after taking into account the proposed Transfer) greater than the Target Voting Power, such Person agrees to transfer shares of Series B Common Stock of such Group to the Company in exchange for shares of Series C Common Stock of such Group on a one to one basis so that such Person’s beneficial ownership of shares of such Group as a percentage of the voting power of all outstanding Voting Securities of such Group does not exceed by more than 0.5% the Target Voting Power of such Group; *provided* that such transfer requirement may be satisfied, with respect to any Available Series B Shares subject of such Successor Exchange Agreement, by execution of such Successor Exchange Agreement.

“Surviving Company” means the entity whose securities are received by Dr. Malone or the Trust in a Fundamental Event.



“Target Voting Power” means 49.0%.

“Tax” or “Taxes” means (a) any and all federal, state, local and foreign taxes and other assessments, governmental charges, duties, fees, levies and liabilities in the nature of a tax, including gross receipts, income, profits, sales, use, occupation, value added, ad valorem, transfer, franchise, withholding, payroll, recapture, escheat, employment, excise and property taxes and (b) all interest, penalties and additions imposed with respect to such amounts in clause (a).

“Tax Return” means a report, return, certificate, form or similar statement or document, including any amendment thereof or any attachment thereto, supplied to or filed with or required to be supplied to or filed with a Governmental Authority in connection with the determination, assessment or collection of any Tax, including an information return, claim for refund, amended return or declaration of estimated Tax.

“Transfer” means a sale, transfer or disposition of beneficial ownership, directly or indirectly, whether by operation of law or otherwise; *provided, however*, the granting of any proxy or the agreement to vote any Voting Securities, in each case in connection with a Fundamental Event, will not be deemed a Transfer of beneficial ownership of the underlying shares.

“Trust” has the meaning set forth in the preamble.

“Voting Power Demand” has the meaning set forth in Section 5(a).

“Voting Power Exchange” has the meaning set forth in Section 5(c)(iii).

“Voting Power Exchange Closing” has the meaning set forth in Section 5(b).

“Voting Securities” shall (i) with respect to the Company, have the meaning set forth in the Company Charter, together with any shares of a new class or series of capital stock of the Company issued after the date hereof which by the terms of any amendment to the Company Charter (including through the effectiveness of a Preferred Stock Designation (as defined in the Company Charter)) is designated as a Voting Security and (ii) with respect to a Surviving Company, mean stock of any class or series entitled to vote generally in the election of directors (or, with respect to any entity that is not a corporation, any equity interest entitled to vote generally in the election of the governing body of such entity).

## 2. Exchange Upon Dilutive Events.

(a) If the Company proposes to consummate any Dilutive Event with respect to a Group or receives notice of any occurrence, event or fact that would reasonably be expected to cause, or has caused, a Dilutive Event with respect to a Group and, in each case, the number of Available Series B Shares of such Group at the time of such Dilutive Event is a positive number, the Company shall provide prompt written notice to Dr. Malone (a “Dilutive Event Notice”), specifying the number and series of the shares of Voting Securities involved in such Dilutive Event, the nature and timing of the Dilutive Event, the Group with respect to which the Dilutive Event has occurred or will occur, a reasonable estimate of the Malone Voting Power in such Group after giving effect to such Dilutive Event (for the avoidance of doubt, without giving effect to any Dilutive Event Exchange in respect thereof) and a reasonable estimate of the number of shares of Series C Common Stock of such Group to be exchanged by Dr. Malone and the Trust collectively in connection with such Dilutive Event.

(b) Subject to the last sentence of Section 2(c), the consummation and closing of any Dilutive Event Exchange will take place as promptly as practicable following the latest to occur of (x) the receipt of a Dilutive Event Notice by Dr. Malone, (y) the occurrence of the Dilutive Event, and (z) the receipt of any necessary regulatory approvals required for Dr. Malone and the Company to complete such Dilutive Event Exchange (including pursuant to the HSR Act or any other Competition Law) (the “Dilutive Event Exchange Closing”), and at a location and time agreed to by Dr. Malone and the Company; *provided, however*, that the conditions set forth in Sections 10, 11 and 12 shall have been satisfied (or waived by the party entitled to the benefit thereof).

- The number of shares of Series C Common Stock of a Group which shall be exchanged by Dr. Malone and/or the Trust in the Dilutive Event Exchange shall be an amount equal to the lesser of (x) the number of shares of Series B Common Stock of the same Group, the beneficial ownership of which by Dr. Malone or the Trust would cause the Malone Voting Power of such Group immediately following the consummation and closing of such Dilutive Event Exchange to be as close as possible to being equal to, but without being greater than, the Target Voting Power, and (y) the number of Available Series B Shares of such Group at such time. The Company shall determine such number of shares to be exchanged and provide Dr. Malone with notice of the same at least five Business Days prior to the Dilutive Event Exchange Closing (which notice may be included in a Dilutive Event Notice); *provided, however*, that Dr. Malone may elect to exchange fewer (or no) shares of such Series C Common Stock upon written notice to the Company.
- (c)
- (d) At any Dilutive Event Exchange Closing, on the terms and subject to the conditions contained in this Agreement (including after giving effect to any adjustments in accordance with Section 19(d) hereof):
- (i) Dr. Malone and the Trust, as applicable, shall convey, transfer and deliver to the Company their respective number of shares of Series C Common Stock of the applicable Group determined in accordance with Section 2(c), free and clear of all Encumbrances other than Permitted Encumbrances;
- (ii) the Company shall issue and/or deliver to Dr. Malone and the Trust, as applicable, such number of shares of Series B Common Stock of the same Group as is equal to such number of shares of Series C Common Stock of such Group delivered by Dr. Malone and the Trust, respectively, and such shares of Series B Common Stock shall be duly authorized, validly issued, fully paid and nonassessable and free and clear of all Encumbrances other than Permitted Encumbrances; and
- (iii) the Company and Dr. Malone and the Trust, as applicable, will duly execute and deliver a cross receipt each acknowledging the receipt of the shares of Common Stock delivered to it in connection therewith (the transactions described in this clause (d) being a “Dilutive Event Exchange”).

### 3. Reverse Exchange Upon Accretive Events.

- If the Company proposes to consummate any Accretive Event with respect to a Group or receives notice of any occurrence, event or fact that would reasonably be expected to cause, or has caused, an Accretive Event with respect to a Group, the Company shall provide prompt written notice to Dr. Malone (an “Accretive Event Notice”), specifying the number and series of the shares of Voting Securities involved in such Accretive Event, the nature and timing of the
- (a) Accretive Event, the Group with respect to which the Accretive Event has occurred or will occur, a reasonable estimate of the Malone Voting Power in such Group after giving effect to such Accretive Event (for the avoidance of doubt, without giving effect to any Reverse Exchange in respect thereof) and a reasonable estimate of the number of Reverse Exchange Shares of such Group to be exchanged by Dr. Malone and the Trust collectively in connection with such Accretive Event.

- Within five (5) Business Days after receipt of an Accretive Event Notice by Dr. Malone or on the closing date provided in such Accretive Event Notice and, to the extent practicable, prior to or concurrently with the consummation of the Accretive Event (or, in the case of subsection (ii) of the definition of Accretive Event, prior to the occurrence of the Accretive Event), Dr. Malone or the Trust and the Company shall consummate a Reverse Exchange (the “Reverse Exchange Closing”) at a location and time agreed to by Dr. Malone and the Company; *provided, however*, that the conditions set forth in Sections 10, 11 and 12 shall have been satisfied (or waived by the party entitled to the benefit thereof).
- (b)

- (c) At a Reverse Exchange Closing, on the terms and subject to the conditions contained in this Agreement (including after giving effect to any adjustments in accordance with Section 19(d) hereof):

- (i) Dr. Malone or the Trust shall convey, transfer and deliver to the Company shares of Series B Common Stock of the Group which was the subject of the Accretive Event in the amount necessary to cause the Malone Voting Power in such Group to be as close as possible to being equal to, but without being greater than, the Target Voting Power after giving effect to such Accretive Event and Reverse Exchange Closing (such shares of the applicable Group, the “Reverse Exchange Shares”), free and clear of all Encumbrances other than Permitted Encumbrances;
- (ii) the Company shall issue and/or deliver to Dr. Malone and the Trust, as applicable, such number of shares of Series C Common Stock of the same Group as is equal to such number of Reverse Exchange Shares of such Group delivered by Dr. Malone and the Trust, respectively, and such shares shall be duly authorized, validly issued, fully paid and nonassessable and free and clear of all Encumbrances other than Permitted Encumbrances; and
- (iii) the Company and Dr. Malone and the Trust, as applicable, will duly execute and deliver a cross receipt each acknowledging the receipt of the shares of Common Stock delivered to it in connection therewith (the transactions described in this clause (c) being a “Reverse Exchange”).

#### 4. Exchange Upon Fundamental Events.

- (a) Subject to Sections 4(b) and (c), in the event that the Company proposes to consummate a Fundamental Event in respect of one or more Groups, then, the Company shall elect (with such election to be at the Company’s sole discretion as approved by a Special Committee or a majority of the Independent Directors), with respect to each such affected Group, that either
- (i) the Company shall provide for Dr. Malone or the Trust to receive the same per share amount and form of consideration for each Malone Series C Exchangeable Share of such Group then outstanding and beneficially owned by Dr. Malone or the Trust as the per share amount and form of consideration to be received by holders of Series B Common Stock of such Group in such Fundamental Event, and Dr. Malone or the Trust, as applicable, will waive (or cause to be waived) the right to receive the consideration that otherwise would be received with respect to such Malone Series C Exchangeable Shares of such Group; or
- (ii) immediately prior to the consummation of such Fundamental Event, the Company and Dr. Malone shall consummate, and the Company and the Trust shall separately consummate, an exchange whereby (x) the Company shall issue and/or deliver to Dr. Malone and/or the Trust, as applicable, one share of Series B Common Stock of the applicable Group for each Malone Series C Exchangeable Share of the same Group then outstanding and beneficially owned by Dr. Malone or the Trust, respectively, and (y) Dr. Malone and/or the Trust, as applicable, shall deliver to the Company their respective Malone Series C Exchangeable Shares of such Group, which shall result in Dr. Malone and the Trust holding shares of Series B Common Stock of such Group (in lieu of such Malone Series C Exchangeable Shares of such Group) that are entitled to receive the same per share amount and form of consideration to be received by Dr. Malone and the Trust, respectively, for his or its other shares of Series B Common Stock of such Group (a “Fundamental Event Exchange” and the consummation of a Fundamental Event Exchange, a “Fundamental Event Exchange Closing”); *provided, however*, that the conditions set forth in Sections 10, 11 and 12 shall have been satisfied (or waived by the party entitled to the benefit thereof). At a Fundamental Event Exchange Closing, if applicable, the Company and Dr. Malone and the Trust, as applicable, will duly execute and deliver a cross receipt each acknowledging the receipt of the shares of Common Stock delivered to it in connection therewith.

- (b) If pursuant to the Fundamental Event in respect of a particular Group, the type, form and amount of consideration to be received by holders of Series B Common Stock and Series C Common Stock of such Group is identical, then Section 4(a) shall be inapplicable with respect to the Fundamental Event at such Group.

- (c) Notwithstanding the discretion afforded to the Company in Section 4.1(a), if its election of Section 4(a)(i) over Section 4(a)(ii) (or vice versa) would (x) have a materially more adverse effect from a taxation or regulatory perspective on Dr. Malone or the Trust than the option not so elected and (y) have no material economic, taxation or regulatory benefit to the Company greater than the option not so elected, the Company shall not be entitled to make such election without the prior written consent of Dr. Malone.

5. Voting Power Exchange.

- If on (x) the last day of any calendar quarter or (y) a date that is at least five but no more than ten Business Days prior to the record date for any matter submitted to the stockholders of the Company for a vote, the Malone Voting Power in the Company would be less than the Target Voting Power if some or all Available Series B Shares of one or more Groups were delivered to Dr. Malone or the Trust as of such date (the number of Available Series B Shares that may be delivered without resulting in the Malone Voting Power in the Company exceeding the Target Voting Power, the "Maximum Amount"), Dr. Malone and the Trust may demand (a "Voting Power Demand") that the Company exchange the Maximum Amount of Available Series B Shares of any or all Groups on a one for one basis for shares of Series C Common Stock of such Group or Groups notwithstanding that immediately following such exchange the Malone Voting Power would exceed the Target Voting Power for any one or more Groups; *provided*, that (a) following any such exchange, the Malone Voting Power in the Company must be less than or equal to the Target Voting Power and (b) with respect to any Group where the Malone Voting Power would exceed the Target Voting Power immediately following such exchange, Dr. Malone and the Trust hereby agree that on any matter submitted by the Company to the stockholders of that Group, voting together as a separate class, for approval, Dr. Malone and the Trust will vote, or cause to be voted, the Voting Securities of such Group beneficially owned by them that represent voting power in excess of the Target Voting Power of such Group in the same manner and in the same proportion as voted by the holders of Voting Securities of that Group other than Dr. Malone and any holder of Voting Securities beneficially owned by Dr. Malone, and his or their Controlled Affiliates (the "Other Voting Securities"), such that, for any such matter, the Voting Securities beneficially owned by Dr. Malone in excess of the Target Voting Power of such Group shall reflect voting results with respect to "shares voted for", "shares voted against", "shares abstained", "broker non-votes" and "shares not present at the meeting" proportionate to such aggregate voting results for the Other Voting Securities.

- (b) No later than four (4) Business Days after the receipt by the Company of written notice by Dr. Malone or the Trust of a Voting Power Demand (which notice shall specify the number of Voting Securities beneficially owned by Dr. Malone with respect to each Group and with respect to the Company), Dr. Malone or the Trust and the Company shall consummate a Voting Power Exchange (the "Voting Power Exchange Closing") at a location and time agreed to by Dr. Malone and the Company; *provided, however*, that the conditions set forth in Sections 10, 11 and 12 shall have been satisfied (or waived by the party entitled to the benefit thereof).

- (c) At any Voting Power Exchange Closing, on the terms and subject to the conditions contained in this Agreement (including after giving effect to any adjustments in accordance with Section 19(d) hereof):

- (i) Dr. Malone and the Trust, as applicable, shall convey, transfer and deliver to the Company a number of shares of Series C Common Stock of one or more Groups in an amount up to the Maximum Amount of Available Series B Shares of such Group or Groups, free and clear of all Encumbrances other than Permitted Encumbrances;

- the Company shall issue and/or deliver to Dr. Malone and the Trust, as applicable, such number of shares of Series B Common Stock of the same Group or Groups as is equal to such number of shares of Series C
- (ii) Common Stock of such Group or Groups delivered by Dr. Malone and the Trust, respectively, and such shares of Series B Common Stock shall be duly authorized, validly issued, fully paid and nonassessable and free and clear of all Encumbrances other than Permitted Encumbrances; and

- (iii) the Company and Dr. Malone and the Trust, as applicable, will duly execute and deliver a cross receipt each acknowledging the receipt of the shares of Common Stock delivered to it in connection therewith (the transactions described in this clause (c) being a “Voting Power Exchange”).

6. Rescission. If the applicable Exchange Event is not consummated either prior to or within ten (10) Business Days following an Exchange Closing, or following a Voting Power Exchange Closing in connection with a stockholder meeting, the applicable meeting of stockholders is cancelled,

- (a) the applicable Exchange will be automatically rescinded and treated as if neither the Exchange nor the Exchange Closing had ever occurred (the “Rescission”);

- each of the Company, Dr. Malone and the Trust hereby waives, and none of the Company, Dr. Malone or the Trust shall have, any rights, duties or obligations of any kind (other than rights, duties or obligations to effect the Rescission) in respect of the Exchange to receive or retain, (x) in the case of Dr. Malone and the Trust, (A) following any Dilutive Event Exchange Closing, any shares of Series B Common Stock issued or delivered in connection therewith; (B) following any Reverse Exchange Closing, any shares of Series C Common Stock issued or delivered in connection therewith; (C) following any Fundamental Event Exchange Closing, any shares of Series B Common Stock issued or delivered in connection therewith; and (D) following a Voting Power Exchange Closing, any shares of Series B Common Stock issued or delivered in connection therewith (such shares referred to in clauses (A), (B), (C) and (D), collectively the “Malone Rescission Shares”), and, (y) in the case of the Company, (A) following any Dilutive Event Exchange Closing, any shares of Series C Common Stock delivered in connection therewith; (B) following any Reverse Exchange Closing, any Reverse Exchange Shares delivered in connection therewith; (C) following any Fundamental Event Exchange Closing, any shares of Series C Common Stock delivered in connection therewith; and (D) following a Voting Power Exchange Closing, any shares of Series C Common Stock delivered in connection therewith (such shares referred to in clauses (A), (B), (C) and (D), collectively the “Company Rescission Shares”); and

- (c) each of the Company, on the one hand, and Dr. Malone and the Trust, on the other hand, will take such actions as are reasonably necessary to effect such Rescission, and each will be deemed, upon the effectiveness of such Rescission, to make appropriate representations and warranties to the other with respect to the valid issuance and conveyance, as applicable, and the lack of any Encumbrances upon the Malone Rescission Shares or the Company Rescission Shares (other than Permitted Encumbrances), as applicable, so as to vest in the other good and valid title to the Malone Rescission Shares or the Company Rescission Shares, as applicable.

7. Representations.

- (a) Representations of Dr. Malone. Dr. Malone, on behalf of himself individually and as trustee of the Trust, represents and warrants to the Company that:

- (i) as of the date of this Agreement, Dr. Malone beneficially owns the number of shares of each series and Group of Common Stock set forth on Exhibit A hereto;

- (ii) (w) as of any Dilutive Event Exchange Closing, Dr. Malone will beneficially own or own of record such number of shares of Series C Common Stock of the applicable Group to be delivered and exchanged by Dr. Malone or the Trust at the Dilutive Event Exchange Closing, free and clear of all Encumbrances other than Permitted Encumbrances, (x) as of any Reverse Exchange Closing, Dr. Malone will beneficially own or

own of record such number of Reverse Exchange Shares of the applicable Group to be delivered and exchanged by Dr. Malone or the Trust at the Reverse Exchange Closing, free and clear of all Encumbrances other than Permitted Encumbrances, (y) as of any Fundamental Event Exchange Closing, Dr. Malone will beneficially own or own of record such number of Malone Series C Exchangeable Shares of the applicable Group to be delivered and exchanged by Dr. Malone or the Trust at the Fundamental Event Exchange Closing, free and clear of all Encumbrances other than Permitted Encumbrances, and (z) as of any Voting Power Exchange Closing, Dr. Malone will beneficially own or own of record such number of shares of Series C Common Stock of the applicable Group or Groups to be delivered and exchanged by Dr. Malone or the Trust at the Voting Power Exchange Closing, free and clear of all Encumbrances other than Permitted Encumbrances;

- (iii) upon delivery to the Company of the shares of Series C Common Stock, Reverse Exchange Shares or Malone Series C Exchangeable Shares at the applicable Exchange Closing, in the manner provided in this Agreement, the Company will have good and valid title to such shares of Series C Common Stock, Reverse Exchange Shares or Malone Series C Exchangeable Shares, free and clear of all Encumbrances other than Permitted Encumbrances and Encumbrances created by the Company or any of its Controlled Affiliates;
- (iv) the Trust is a trust duly organized and validly existing under the Laws of the State of Florida and each of Dr. Malone and the Trust have all requisite legal capacity to execute and deliver this Agreement and to perform their obligations under this Agreement, including any Exchange and the other transactions contemplated hereby;
- (v) this Agreement has been duly and validly executed and delivered by Dr. Malone and the Trust and, assuming the due execution and delivery hereof by the Company, is a valid and binding agreement of Dr. Malone and the Trust, enforceable in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally, or by principles governing the availability of equitable remedies;
- (vi) the execution, delivery and performance by Dr. Malone and the Trust of this Agreement and the consummation by Dr. Malone or the Trust of any Exchange and the other transactions contemplated hereby requires no action by or in respect of, or filings with, any Governmental Authority other than (x) as may be required by Competition Laws, including the HSR Act, (y) such clearances, consents, approvals, Orders, licenses, authorizations, registrations, declarations, permits, filings and notifications as may be required under applicable securities Laws and (z) any actions or filings under Laws (other than Competition Laws) the absence of which would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the ability of Dr. Malone or the Trust to consummate any Exchange or the other transactions contemplated hereby, or prevent or materially delay the consummation of any Exchange or the other transactions contemplated by this Agreement;
- (vii) the execution and delivery of this Agreement, and the performance by Dr. Malone and the Trust of this Agreement and the consummation by Dr. Malone or the Trust of any Exchange and the other transactions contemplated hereby will not (x) violate any applicable Law, (y) conflict with or constitute a default, breach or violation of (with or without notice or lapse of time, or both) the terms, conditions or provisions of, or result in the acceleration of (or the creation in any Person of any right to cause the acceleration of) any performance of any obligation or any increase in any payment required by, or the termination, suspension, modification, impairment or forfeiture (or the creation in any Person of any right to cause the termination, suspension, modification, impairment or forfeiture) of any contract, agreement or instrument to which Dr. Malone or the Trust is subject, which would prevent Dr. Malone or the Trust from performing any of their obligations hereunder, or (z) require any consent by or approval of or notice to any other Person or entity (other than a Governmental Authority), except, in the case of clauses (x), (y) and (z), as would not have a material adverse effect, individually or in the aggregate, on Dr. Malone's or the Trust's ability to consummate any Exchange or the other transactions contemplated hereby, or prevent or materially delay the consummation of any Exchange or the other transactions contemplated by this Agreement; and

(viii) each of Dr. Malone and the Trust is a sophisticated investor and an accredited investor (as defined in Rule 501(a) of Regulation D of the Securities Act), with sufficient knowledge and experience in financial and business matters to evaluate the merits and risks of any Exchange, and the other transactions contemplated hereby, and each of Dr. Malone and the Trust acknowledges that the offer and sale of any Company Exchange Shares hereunder has not been registered under the Securities Act or any securities Laws of any state and that such Company Exchange Shares may not be sold, transferred, offered for sale, pledged, hypothecated or otherwise disposed of without registration under the Securities Act, except pursuant to an exemption from such registration available under the Securities Act.

(b) Representations of the Company. The Company represents and warrants to Dr. Malone and the Trust that:

- (i) upon issuance and/or delivery to Dr. Malone or the Trust of the Company Exchange Shares at an Exchange Closing in the manner provided in this Agreement, such Company Exchange Shares will be duly authorized, validly issued, fully paid and nonassessable and Dr. Malone or the Trust, as applicable, will have good and valid title to such Company Exchange Shares so delivered, free and clear of all Encumbrances other than Permitted Encumbrances and Encumbrances created by Dr. Malone or any of his Affiliates;
- (ii) the Company is a Delaware corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware, and has full power and authority to execute and deliver this Agreement and to consummate any Exchange and the other transactions contemplated hereby;
- (iii) the execution and delivery of this Agreement by the Company, and performance of this Agreement by the Company, including the consummation of any Exchange and the other transactions contemplated hereby, has been duly authorized by all requisite corporate power;

(iv) this Agreement has been duly and validly executed and delivered by the Company and, assuming the due execution and delivery hereof by Dr. Malone and the Trust, is a valid and binding agreement of the Company, enforceable in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally, or by principles governing the availability of equitable remedies;

(v) the execution, delivery and performance by the Company of this Agreement and the consummation by the Company of any Exchange, and the other transactions contemplated hereby requires no action by or in respect of, or filings with, any Governmental Authority, other than (x) as may be required by any Competition Laws, including the HSR Act, (y) such clearances, consents, approvals, Orders, licenses, authorizations, registrations, declarations, permits, filings and notifications as may be required under applicable securities Laws and (z) any actions or filings under Laws (other than Competition Laws) the absence of which would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the ability of the Company to consummate any Exchange or the other transactions contemplated hereby or prevent or materially delay the consummation of any Exchange or the other transactions contemplated by this Agreement; and

(vi) the execution, delivery and performance by the Company of this Agreement and the consummation of any Exchange and the other transactions contemplated hereby will not (x) violate any applicable Law, (y) conflict with or constitute a default, breach or violation of (with or without notice or lapse of time, or both) the terms, conditions or provisions of, or result in the acceleration of (or the creation in any Person of any right to cause the acceleration of) any performance of any obligation or any increase in any payment required by, or the

termination, suspension, modification, impairment or forfeiture (or the creation in any Person of any right to cause the termination, suspension, modification, impairment or forfeiture) of any contract, agreement or instrument to which the Company is subject, including without limitation the Company Charter, the Company Bylaws or similar organization documents of any of the Company's Controlled Affiliates, which would prevent it from performing any of its obligations hereunder, or (z) require any consent by or approval of or notice to any other Person or entity (other than a Governmental Authority), except, in the case of clauses (x), (y) and (z), as would not have a material adverse effect, individually or in the aggregate, on the Company's ability to consummate any Exchange and the other transactions contemplated hereby, or prevent or materially delay the consummation of any Exchange and the other transactions contemplated by this Agreement.

8. Reasonable Best Efforts and Other Covenants.

(a) The Company, Dr. Malone and the Trust shall cooperate with each other and use their reasonable best efforts to (i) consummate any Exchange and any other transactions contemplated by this Agreement in the manner contemplated by this Agreement and (ii) execute documents reasonably necessary to effect any Exchange and any other transactions contemplated by this Agreement.

(b) The Company, Dr. Malone and the Trust shall cooperate with each other and shall prepare and file all necessary filings, applications, notices and/or similar instruments or documentation, and use their respective reasonable best efforts to obtain as promptly as practicable all consents, approvals or non-objections, as applicable, of all third parties and Governmental Authorities that, in each case, are required under applicable Law to consummate any Exchange and the other transactions contemplated by this Agreement.

(c) Dr. Malone (directly or through his executors, administrators, or testamentary trustees) may Transfer the right to receive Available Series B Shares of any one or more Groups to, and only to (i) prior to Dr. Malone's death or incapacity, a Proposed Transferee who prior to such Transfer executes a Successor Exchange Agreement covering all shares of Series B Common Stock of such Group then beneficially owned by Dr. Malone and all Available Series B Shares of such Group or (ii) a Proposed Transferee who, within three months of Dr. Malone's death or incapacity, executes a Successor Exchange Agreement covering all shares of Series B Common Stock of such Group beneficially owned by Dr. Malone immediately prior to his death or incapacity and all Available Series B Shares of such Group; *provided*, that any Available Series B Shares hereunder may be released or exchanged to such a Proposed Transferee only following the execution of a Successor Exchange Agreement on the terms and subject to the conditions of such Successor Exchange Agreement. For the avoidance of doubt, neither Dr. Malone nor the Trust shall Transfer the right to obtain any Available Series B Shares (including through a series of one or more Transfers of Series B Common Stock (including Available Series B Shares issued and/or delivered in a Dilutive Event Exchange) to the same Person or Persons) except to a Proposed Transferee pursuant to a Successor Exchange Agreement, and Available Series B Shares hereunder may be released or exchanged only on the terms and subject to the conditions of this Agreement or a Successor Exchange Agreement. The Company shall negotiate in good faith a Successor Exchange Agreement with each Proposed Transferee to whom Dr. Malone (directly or through his executors, administrators or testamentary trustees) seeks to Transfer Available Series B Shares pursuant to this Section 8(c).

(d) Dr. Malone shall promptly provide notice to the Company of any Transfer or acquisition by Dr. Malone or the Trust of any Voting Securities.

(e) Unless otherwise determined by a Special Committee or a majority of the Independent Directors, in connection with any Fundamental Event involving (i) a split-off or spin-off or (ii) a combination, consolidation or merger as a result of which the stockholders of the Company are entitled to receive all or substantially all of the Voting Securities of the



Surviving Company and, in each case, Dr. Malone would (A) serve as an officer or director of the Surviving Company entitling him to the exemptions provided by Rule 16b-3 promulgated under the Exchange Act if an Exchange were approved by the board of directors of the Surviving Company or a committee of such board of directors composed solely of two or more Non-Employee Directors (as defined in such Rule) and (B) beneficially own 40% or more of the outstanding voting power of the Surviving Company, Dr. Malone, the Trust and the Company (acting through a Special Committee or the Independent Directors) shall, and shall cause the Surviving Company to, negotiate an exchange agreement with respect to the Surviving Company in substantially the form of this Agreement in order to replicate the benefits and obligations of Dr. Malone, the Trust and the Company as exist under this Agreement as of the effective time of such Fundamental Event.

- (f) In the event Dr. Malone no longer serves as an officer or director of the Company such that Rule 16b-3 promulgated under the Exchange Act would not be available to exempt the Exchange transactions hereunder, then neither Dr. Malone nor the Trust shall be required to participate in any Exchange (including, without limitation any Reverse Exchange) that would result in liability under Section 16(b) of the Exchange Act.

- Tax Matters. Each of the Company, the Trust and Dr. Malone acknowledges and agrees that each Exchange is a transaction intended to qualify, for U.S. federal income tax purposes, as an exchange pursuant to Section 1036(a) of the Code and/or a reorganization under Section 368(a)(1)(E) of the Code, in either case, which is tax-free except to the extent of any consideration received by the Trust or Dr. Malone other than Company Exchange Shares, and except to the extent otherwise required pursuant to a “determination” (within the meaning of Section 1313(a) of the Code) or a change in applicable Tax Law occurring after the date of this Agreement, the Company, the Trust and Dr. Malone agree not to take any position on any Tax Return, or take any position for Tax purposes, that is inconsistent with any Exchange qualifying for U.S. federal income tax purposes as an exchange under Section 1036(a) of the Code and/or a reorganization under Section 368(a)(1)(E) of the Code which is tax-free except to the extent of any consideration received by the Trust or Dr. Malone other than Company Exchange Shares; provided, that in the event of a Rescission, the Company, the Trust and Dr. Malone shall not take any position on any Tax Return, or take any position for Tax purposes, that is inconsistent with an Exchange and any exchange effecting a Rescission (a “Rescission Exchange”) qualifying, for U.S. federal income tax purposes, either (A) to the extent the Exchange and a corresponding Rescission Exchange occur in the same tax year, as disregarded transactions or exchanges under Section 1036(a) of the Code which are disregarded or tax-free, as applicable, except to the extent of any consideration received by the Trust or Dr. Malone other than Company Exchange Shares and Company Rescission Shares, or (B) to the extent the Exchange and the corresponding Rescission Exchange occur in different tax years, as exchanges under Section 1036(a) of the Code which are tax-free except to the extent of any consideration received by the Trust or Dr. Malone other than Company Exchange Shares and Company Rescission Shares. For the avoidance of doubt, consideration received by the Trust or Dr. Malone includes, as applicable, any costs or expenses paid on behalf of or reimbursed to the Trust or Dr. Malone. This Agreement shall constitute a “plan of reorganization” within the meaning of Sections 1.368-2(g) and 1.368-3(a) of the U.S. Treasury Regulations promulgated under the Code with respect to each Exchange under this Agreement. At each Exchange Closing, Dr. Malone and the Trust shall each provide to the Company a valid executed Internal Revenue Service Form W-9 (or applicable successor form) reasonably satisfactory to the Company with respect to Dr. Malone and the Trust, respectively.

10. Conditions to Parties’ Obligation to Effect an Exchange. The respective obligations of the Company, Dr. Malone and the Trust to effect any Exchange shall be subject to the satisfaction, by each of Dr. Malone, the Trust and the Company prior to or at the relevant Exchange Closing of the following conditions:

- (a) No Injunctions or Restraints. No Order entered, enacted, promulgated, enforced or issued by any court or other Governmental Authority of competent jurisdiction, shall be in effect which prohibits, renders illegal or enjoins the consummation of such Exchange; and
- (b) Occurrence of Event.
- (i) Dilutive Event. In the case of a Dilutive Event Exchange, the relevant Dilutive Event shall have occurred.
- (ii) Accretive Event. In the case of a Reverse Exchange, the relevant Accretive Event shall have already occurred or be reasonably expected to occur concurrently with or promptly following the Reverse Exchange.

- (iii) Fundamental Event. In the case of a Fundamental Event Exchange, the relevant Fundamental Event shall be reasonably expected to occur immediately following the Fundamental Event Exchange.

11. Conditions to the Company's Obligation to Effect an Exchange. The obligation of the Company to effect any Exchange is also subject to the satisfaction, or (to the extent legally permissible) waiver in writing by the Company, prior to or at the relevant Exchange Closing of the following conditions:

- (a) Representations and Warranties. The representations and warranties of Dr. Malone and the Trust set forth in Section 7(a) shall be true and correct in all material respects in each case as of the date of this Agreement and as of the Exchange Closing as though made on and as of the Exchange Closing, except for (x) those representations and warranties made as of a specified date, which shall be true and correct in all material respects as of such date, and (y) *de minimis* inaccuracies;

---

20

---

- (b) Covenants. Dr. Malone and the Trust shall have performed in all material respects all covenants required to be performed by them prior to or at such Exchange Closing; and

- (c) Closing Certificate. Dr. Malone and the Trust shall have delivered to the Company a certificate duly signed by Dr. Malone, individually and as trustee of the Trust, that the conditions set forth in Sections 11(a) and (b) have been satisfied.

12. Conditions to Dr. Malone's and the Trust's Obligation to Effect an Exchange. The obligation of Dr. Malone and the Trust to effect any Exchange is also subject to the satisfaction, or (to the extent legally permissible) waiver in writing by Dr. Malone (individually and as trustee of the Trust), prior to or at the relevant Exchange Closing of the following conditions:

- (a) Representations and Warranties. The representations and warranties of the Company set forth in Section 7(b) shall be true and correct in all material respects in each case as of the date of this Agreement and as of the Exchange Closing as though made on and as of the Exchange Closing, except for (x) those representations and warranties made as of a specified date, which shall be true and correct in all material respects as of such date, and (y) *de minimis* inaccuracies;

- (b) Covenants. The Company shall have performed in all material respects all other covenants required to be performed by it prior to or at such Exchange Closing;

- (c) Section 16b-3. The Board or a committee of the Board composed solely of two or more Non-Employee Directors (as defined in Rule 16b-3 promulgated under the Exchange Act) shall have adopted resolutions exempting the Exchange under Rule 16b-3 promulgated under the Exchange Act; and

- (d) Officer's Certificate. The Company shall have delivered to Dr. Malone and the Trust a certificate duly signed by a duly authorized officer of the Company that the conditions set forth in Sections 12(a), (b) and (c) have been satisfied.

13. Termination.

- (a) This Agreement will terminate and no longer apply with respect to the Common Stock of any particular Group beneficially owned by Dr. Malone (i) upon the mutual consent of each of the parties hereto in a written instrument (in the case of the Company, upon the approval of a Special Committee or a majority of Independent Directors), (ii) upon execution of a Successor Exchange Agreement covering all shares of Series B Common Stock of such Group then beneficially owned by Dr. Malone and all Available Series B Shares of such Group or (iii) other than in a circumstance where this Agreement is terminated pursuant to Section 13(a)(ii), upon the Malone Voting Power ceasing to constitute at least 20% of the outstanding voting power of such Group.

---

21

---

(b) This Agreement will terminate in its entirety and immediately cease to be of any further force and effect (i) pursuant to the mutual consent of each of the parties hereto in a written instrument (in the case of the Company, upon the approval of a Special Committee or a majority of Independent Directors), (ii) upon execution of a Successor Exchange Agreement covering all shares of Series B Common Stock then beneficially owned by Dr. Malone and all Available Series B Shares of all Groups, or (iii) other than in a circumstance where this Agreement is terminated pursuant to Section 13(b)(ii), upon the Malone Voting Power ceasing to constitute at least 20% of the outstanding voting power of the Company.

(c) If this Agreement is terminated in accordance with Section 13(b), this Agreement shall forthwith become null and void and of no effect and the rights and obligations of the parties hereto shall terminate, without liability of any party (or any stockholder, director, officer, employee, consultant, financial advisor, legal counsel, financing source, accountant, insurer or other advisor, agent or representative of such party); *provided*, that, (i) in the event of a termination as a result of the death of Dr. Malone, the Company's obligation in the last sentence of Section 8(c) shall survive for three months following such termination and (ii) nothing contained herein shall relieve any party to this Agreement from any liability for damages resulting from (x) fraud or (y) willful material breach by such party prior to such termination, in each case, as determined by a court of competent jurisdiction pursuant to a final and nonappealable judgment. For purposes of this Agreement, "willful material breach" means a material breach of a party's covenants and agreements set forth in this Agreement that is the consequence of an act or omission by a party with the knowledge that the taking of such act or failure to take such action would be a material breach of such party's covenants or agreements (*provided*, that, with respect to the Company, knowledge includes the actual knowledge, after due inquiry, of the senior executive management team of the Company).

(d) For the avoidance of doubt, (i) upon the termination of this Agreement with respect to any Group (other than a termination pursuant to Section 13(a)(ii)), any and all Available Series B Shares of such Group, if any, will be immediately and automatically forfeited and cancelled and no Person shall have any right to obtain any such Available Series B Shares of such Group and (ii) upon the termination of this Agreement with respect to the Company (other than a termination pursuant to Section 13(b)(ii)), any and all Available Series B Shares, if any, will be immediately and automatically forfeited and cancelled and no Person shall have any right to obtain any Available Series B Shares; *provided, however*, that upon the termination of this Agreement following the death of Dr. Malone, the executors, administrators or testamentary trustees of Dr. Malone may Transfer the right to receive Available Series B Shares of any one or more Groups pursuant to, and only pursuant to, Section 8(c) hereof.

14. Applicable Law. All disputes, claims or controversies arising out of or relating to this Agreement, or the negotiation, validity or performance of this Agreement, or any Exchange and the other transactions contemplated hereby shall be governed by and construed in accordance with the Laws of the State of Delaware without regard to its rules of conflict of Laws.

15. Jurisdiction. Each of the parties hereto (a) irrevocably and unconditionally consents to submit itself to the sole and exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, or, solely if that court does not have subject matter jurisdiction, the Superior Court of the State of Delaware, or, solely if the subject matter of the Action is one over which exclusive jurisdiction is vested in the courts of the United States of America, a federal court sitting in the State of Delaware (collectively, the "Delaware Courts") in connection with any dispute, claim, or controversy arising out of or relating to this Agreement, any Exchange, or the other transactions contemplated hereby, (b) waives any objection to the laying of venue of any such litigation in any of the Delaware Courts, (c) agrees not to plead or claim in any such court that such litigation brought therein has been brought in an inconvenient forum and agrees not otherwise to attempt to deny or defeat such personal jurisdiction or venue by motion or other request for leave from any such court, and (d) agrees that it will not bring any Action in connection with any dispute, claim, or controversy arising out of or relating to this Agreement or any Exchange and the other transactions contemplated hereby, in any court or other tribunal, other than any of the Delaware Courts. All Actions arising out of or relating to this Agreement or any Exchange and the other transactions contemplated hereby shall be heard and determined in the Delaware Courts. Each of the parties hereto hereby irrevocably and unconditionally agrees that service of process in connection with any dispute, claim, or controversy arising out of or relating to this Agreement, any Exchange and the other transactions contemplated hereby may be made upon such party by prepaid certified or registered mail, with a validated proof of mailing receipt constituting evidence of valid service, directed to such party at the address specified in

Section 18 hereof. Service made in such manner, to the fullest extent permitted by applicable Law, shall have the same legal force and effect as if served upon such party personally within the State of Delaware. Nothing herein shall be deemed to limit or prohibit service of process by any other manner as may be permitted by applicable Law.

- Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY EXCHANGE AND THE OTHER TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVER, (C) IT MAKES SUCH WAIVER VOLUNTARILY AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 16.

- Enforcement of this Agreement. The parties acknowledge and agree that irreparable damage would occur and that the parties would not have any adequate remedy at Law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that monetary damages, even if available, would not be an adequate remedy therefor. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement (without the obligation to post a bond therefor) and to enforce specifically the terms and provisions of this Agreement in the Court of Chancery of the State of Delaware, this being in addition to any other remedy to which they are entitled at Law or in equity.

- Notices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed given (a) on the date of delivery if delivered personally or sent via e-mail or (b) on the first (1st) Business Day following the date of dispatch if sent by a nationally recognized overnight courier (providing proof of delivery), in each case to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):

if to Dr. Malone or the Trust, to:

John C. Malone  
c/o Liberty Media Corporation  
12300 Liberty Boulevard  
Englewood, CO 80112  
E-Mail: [Separately provided]

with a copy (which shall not constitute notice) to:

Sherman & Howard L.L.C.  
633 Seventeenth Street  
Suite 3000  
Denver, CO 80202  
Attention: Steven D. Miller  
Jeffrey R. Kesselman  
E-Mail: [Separately provided]  
[Separately provided]

if to the Company, to:

Liberty Media Corporation  
12300 Liberty Boulevard  
Englewood, CO 80112

with a copy (which shall not constitute notice) to:

Baker Botts L.L.P.  
2001 Ross Avenue  
Suite 900  
Dallas, Texas 75201  
Attention: Samantha Crispin  
Email: [Separately provided]

19. Miscellaneous.

- (a) Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by operation of Law or otherwise by any of the parties hereto without the prior written consent of the other parties hereto (in the case of the Company, acting upon the consent of a Special Committee or a majority of the Independent Directors). Any purported assignment in breach of the foregoing is void *ab initio* and of no force and effect whatsoever. This Agreement is intended for the benefit of the parties hereto and is not for the benefit of, nor may any provision hereof be enforced by, any other Person; *provided, however*, that Dr. Malone's executors, administrators and testamentary trustees may, for three months following Dr. Malone's death, enforce the last sentence of Section 8(c) hereof.
- (b) This Agreement may be executed in separate counterparts, each of which will be an original and all of which taken together will constitute one and the same agreement.
- (c) If, subsequent to the date hereof, further documents are reasonably requested in order to carry out the provisions and purposes of this Agreement, the parties hereto will execute and deliver such further documents.

- (d) When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words "include", "includes" or "including" are used in this Agreement, they shall be deemed to be followed by the words "without limitation". The words "hereof", "herein" and "hereunder" and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. Definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. When this Agreement contemplates a certain number of securities, as of a particular date, such number of securities (including Available Series B Shares) shall be deemed to be appropriately adjusted (without duplication) to account for stock splits, stock dividends, recapitalizations, combinations of shares or other change affecting the outstanding shares of the Common Stock or Voting Securities other than any Fundamental Event subject to Section 4. In the event the Company's stockholders approve an amendment to the Company Charter to change the name of a tracking stock group, references to the prior name of such tracking stock group and its securities in this Agreement shall be deemed to refer to the renamed tracking stock group and its securities.

- (e) Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed (i) in the case of an amendment, by each of parties hereto (in the case of the Company, upon the approval of a Special Committee or a majority of the Independent Directors), and (ii) in the case of a waiver, by the party against whom the waiver is to be effective (in the case of the Company, upon the approval of a Special Committee or a

majority of the Independent Directors). No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

- (f) If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of Law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect, insofar as the foregoing can be accomplished without materially affecting the benefits anticipated by the parties to this Agreement. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible to the fullest extent permitted by applicable Law in an acceptable manner to the end that the Exchanges and the other transactions contemplated hereby are fulfilled to the greatest extent possible.

- (g) The parties acknowledge and confirm that each of their respective attorneys have participated jointly in the drafting, review and revision of this Agreement and that it has not been written solely by counsel for one party and that each party has had the benefit of its independent legal counsel's advice with respect to the terms and provisions hereof and its rights and obligations hereunder. Each party hereto, therefore, stipulates and agrees that the rule of construction to the effect that any ambiguities are to be or may be resolved against the drafting party shall not be employed in the interpretation of this Agreement to favor any party against another and that no party shall have the benefit of any legal presumption or the detriment of any burden of proof by reason of any ambiguity or uncertain meaning contained in this Agreement.

- (h) All costs and expenses incurred or to be incurred with this Agreement and the transactions contemplated hereby will be paid by the party incurring such cost or expense, *provided*, that the Company shall pay (or reimburse Dr. Malone and the Trust) all reasonable out-of-pocket costs and expenses incurred by Dr. Malone and the Trust, including the reasonable fees, charges and disbursements of counsel for Dr. Malone and the Trust and any filing fees due for any filings pursuant to any Competition Law, including the HSR Act, in each case, necessary or in connection with the preparation, negotiation, execution and consummation of this Agreement and any of the transactions contemplated by this Agreement.

*[Signature Page Follows]*

***Execution Version***

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

JOHN C. MALONE

/s/ John C. Malone

JOHN C. MALONE 1995 REVOCABLE TRUST U/A DTD 3/6/  
1995

By: /s/ John C. Malone

Name: John C. Malone

Title: Trustee

---

LIBERTY MEDIA CORPORATION

By: /s/ Renee L. Wilm  
Name: Renee L. Wilm  
Title: Chief Legal Officer

---